Review Article. Upper Urinary Tract Recurrence Following Radical Cystectomy for Bladder Cancer: A Meta-Analysis on 13,185 Patients

Size: px
Start display at page:

Download "Review Article. Upper Urinary Tract Recurrence Following Radical Cystectomy for Bladder Cancer: A Meta-Analysis on 13,185 Patients"

Transcription

1 Review Article Upper Urinary Tract Recurrence Following Radical Cystectomy for Bladder Cancer: A Meta-Analysis on 13,185 Patients Stefano Picozzi,* Cristian Ricci, Maddalena Gaeta, Dario Ratti, Alberto Macchi, Stefano Casellato, Giorgio Bozzini and Luca Carmignani From the Urology Department (SP, DR, AM, SC, GB, LC) and Biometry and Clinical Epidemiology Unit (CR), IRCCS Policlinico San Donato, University of Milan, Milan, and the Hygiene Unit, Department of Preventive and Occupational Medicine, University of Pavia, Pavia (MG), Italy Abbreviations and Acronyms CIS carcinoma in situ TCC transitional cell cancer UUT upper urinary tract Submitted for publication December 8, Supplementary material can be obtained at Nothing to disclose. * Correspondence: Urology Department, IRCCS Policlinico San Donato, Via Morandi 30, San Donato Milanese, Milan Italy (telephone: ; FAX: ; stepico@tin.it). For other articles on related topics see pages 2377, 2384, 2391 and Editor s Note: This article is the first of 5 published in this issue for which category 1 CME credits can be earned. Instructions for obtaining credits are given with the questions on pages 2446 and Purpose: Patients who undergo radical cystectomy for urothelial cancer are at risk for upper urinary tract disease in the remnant transitional tissue. Previous studies have identified several risk factors for upper urinary tract recurrence but the predictive value of each factor remains controversial. Furthermore, the schedule for surveillance of the upper urinary tract with imaging techniques and cytology has not been established. International guidelines do not address these topics and refer only to isolated works with a large case based analysis. We performed this meta-analysis to evaluate the effective incidence of upper urinary tract recurrence after cystectomy for bladder cancer, to analyze the risk factors so we can create subgroups of patients at high risk for recurrence and to investigate the real role of screening in the detection of upper tract lesions at an early stage. Materials and Methods: A bibliographic search covering the period from January 1970 to July 2010 was conducted using PubMed, MEDLINE and EMBASE. This analysis is based on the 27 studies that fulfilled the predefined inclusion criteria. Data were analyzed using a fixed effect logistic regression approach and classic meta-analysis. Results: A total of 13,185 participants were included in the analysis. Followup was described in 22 studies and ranged from 0.36 to months. The overall prevalence of upper tract transitional cell cancer after cystectomy ranged from 0.75% to 6.4%. Recurrence appeared at a range of 2.4 to 164 months, and in an advanced (64.6%) or metastatic state (35.6%) as reflected in poor survival rates. Patients with low grade vs high grade lesions at cystectomy showed as strong a significant difference in incidence as those with carcinoma in situ and superficial cancer vs invasive cancers and as strong as in those without lymph node involvement, with multifocal disease, with a history of multiple urothelial recurrences, with positive ureteral margins, with positive urethral margins, with urethral involvement and a history of upper urinary tract urothelial cancer. Data do not support a statistically significant difference in recurrence among patients with a history of carcinoma in situ, solitary lesion and among various types of urinary diversion adopted. In 24 studies the followup schedule included periodic radiological assessment of the upper urinary tract and in 20 it included urinary cytology. In 14 studies in 63 of 166 patients (38%) upper urinary tract recurrence was diagnosed by followup investigation whereas in the remaining 62% diagnosis was based on symptoms. When urine cytology was used in surveillance the rate of primary detection was 7% and with upper urinary tract imaging it was 29.6%. Of 5,537 patients who underwent routine cytological examination, recurrence was diagnosed in 1.8/1,000 and of those who underwent upper urinary tract imaging recurrence was diagnosed in 7.6/1, /12/ /0 THE JOURNAL OF UROLOGY Vol. 188, , December by AMERICAN UROLOGICAL ASSOCIATION EDUCATION AND RESEARCH, INC. Printed in U.S.A.

2 UPPER URINARY TRACT RECURRENCE FOLLOWING RADICAL CYSTECTOMY 2047 Conclusions: The recurrence values could appear low when considering the pan-urothelial field defect theory, but these values reflect, in part, the mortality associated with the initial bladder cancer. Based on anamnesis and pathological examination of cystectomy specimens, a group of patients is at high risk. Extensive regular followup with cytology, urography and loopgraphy yields insufficient benefits. Periodic computerized tomography with urography combines the ability to study the upper urinary tract oncologically and functionally, and the identification of any parenchymal, osseous or lymph node secondary lesion. Key Words: urinary bladder neoplasms; ureteral neoplasms; carcinoma, transitional cell; recurrence; cystectomy TRANSITIONAL cell carcinoma is often multifocal, and while it most frequently involves the bladder mucosa, the urothelial lining of the renal pelvis, the ureters and the urethra are also at risk. In fact, urothelial carcinoma is thought to be associated with a pan-urothelial field defect characterized by frequent, multifocal metachronous tumors due to the transformation of epithelial cells at different sites, and the intraluminal seeding and implantation of tumor cells derived from an initial clone. 1 Today radical cystectomy is the standard treatment for patients with invasive bladder cancer and for those with superficial disease at high risk for progression. 2,3 Patients who undergo radical cystectomy for urothelial cancer are at risk for UUT disease in the remnant transitional tissue and clearly not all patients have an equal propensity for a UUT tumor. Previous studies identified several risk factors but the predictive value of each factor remains controversial. In addition, the optimal schedule for surveillance, and the role of cytology and imaging techniques have not yet been established. International guidelines do not cover these issues, and refer only to some work with a large case based analysis. 2,3 MATERIALS AND METHODS In this systematic review and meta-analysis we evaluate the effective incidence of UUT recurrence after cystectomy for bladder cancer, analyze the risk factors so we can create subgroups of patients at high risk for recurrence, and study the real role of screening in the detection of upper tract lesions at an early stage. Search Strategy Studies were identified by searching electronic databases and scanning reference lists of articles. A bibliographic search covering January 1970 to July 2010 was conducted using PubMed, MEDLINE and EMBASE. Additional hand searches were performed of the reference lists of included studies, reviews, meta-analyses and guidelines on UUT recurrence after cystectomy. Several search terms were used for each, including bladder cancer, upper urinary tract cancer, cystectomy, recurrence, population based, incidence, treatment, urinary cytology, urography, tomography and followup. The searches were restricted to publications in English. Study Selection Studies were excluded from analysis if they were case reports, meeting abstracts and conference proceedings. Identified studies were reviewed and selected if they reported data related to UUT recurrence after radical cystectomy. The inclusion or exclusion of studies was performed hierarchically based first on the title of the report, then on the abstract and finally on the contents of the full text. A study was accepted for inclusion on the basis of the agreement of 2 investigators (SP and CR). Any disagreement on study inclusion was resolved by consulting a third investigator (LC). Database searches yielded 143 references. Exclusion of irrelevant references left 29 references describing studies. We excluded 2 further references because they were not in English. Thus, this analysis is based on the 27 studies that fulfilled the predefined inclusion criteria. Data Extraction, Quality of Comparative Study and Level of Evidence One author (SP) extracted the data and a second author (CR) checked the extracted data to ensure data quality. Disagreements were resolved by discussion between the 2 review authors, and if no agreement could be reached it was planned that a third author (LC) would decide. The quality of studies was scored using the methods of the U.S. Preventive Services Task Force. 4,5 PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines were applied in the preparation of this report. 6 All the studies included in the meta-analysis were classified as good, 7 32 except that of Akkad et al, 23 which was fair due to the moderate sample size. Statistical Analysis Data were analyzed in 2 ways. If the survey reported incomplete data on exposure (no events reported for a given level), a fixed effect logistic regression approach was applied to all reported outcomes. To correct for overdispersion, the covariance matrix was multiplied by the estimate of the dispersion parameter using Williams or deviance criterion where appropriate. 33 The effects of factors of interest were evaluated by odds ratio estimate and 95% confidence limits. A second approach of meta-analysis was applied to surveys reporting complete data about exposures (the outcomes rate for all factors of interest by study). For this analysis the random or fixed effect model analysis was used according to the heterogeneity among studies (random effect model was used when I 2 was greater than 50%). 34

3 2048 UPPER URINARY TRACT RECURRENCE FOLLOWING RADICAL CYSTECTOMY Evaluation of small study effect and publication bias was performed with funnel plot visual inspection for all of the comparisons and with Harbord-Egger tests where applicable (number of included studies greater than 5). 35 Incomplete data meta-analysis was performed using SAS version and classic meta-analysis was performed using RevMan software version 5.0 (Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2008). RESULTS Analysis of Database Upper urinary tract recurrence is defined as any documented radiographic, endoscopic or pathologically proven recurrence in the renal collecting system or ureter after cystectomy. A total of 13,185 participants were included in the 27 studies examined in this meta-analysis. The number of participants in each survey ranged from 85 to 1,420 (mean 488, median 382). Of the 27 studies 1 was published in the 1970s, 1 in the 1980s, 9 in the 1990s and the remaining 16 after There were 14 studies from the United States, 3 from Japan, 2 from Spain, and Switzerland, Germany, Finland, Korea, Great Britain and Austria provided 1 study each. The interval in which patients were recruited in these studies varied between 5 and 22 years. Patient Characteristics Of the 27 studies 15 reported patient gender, with 7,972 male subjects and 1,638 female for a ratio of 5:1. Thirteen studies reported participant age, with a mean of 64.8 years (median 65, range 23 to 93). Followup was described in 22 studies, and ranged between 0.36 and months. Overall Analysis of Outcomes The overall prevalence of UUT-TCC after cystectomy for muscle invasive or refractory nonmuscle invasive TCC ranged from 0.75% to 6.4%. There were no cases of recurrence due to other types of cancer. This range of recurrence could appear low with respect to the pan-urothelial field defect theory, but this in part reflects the mortality associated with the initial bladder cancer. In addition, cancerous substances eliminated in the urine remain stored and in contact with the bladder mucosa for a consistent time, compared to the pelvic and ureteral mucosa acting in this site for a longer time, thereby promoting cellular malignant transformations. Small Study and Publication Bias Assessment Funnel plot visual inspection did not show publication or small study bias for the comparisons performed as shown in figures 1 and 2, with the exception of history of concomitant CIS vs absent CIS (fig. 2, 9). For this comparison the Egger test did not generate a statistically significant result (p 0.398), whereas the Harbord test result was significant (p ). For the comparison of positive vs negative ureteral margins the absence of publication bias by funnel plot visual inspection was confirmed by the Egger test (p ) but not by the Harbord test (p , fig. 2, 12). Tumor Grading at Cystectomy Bladder cancer was classified as grade 1 (well differentiated), grade 2 (moderately differentiated) and grade 3 (poorly differentiated) according to 1973 WHO grading. We compared the different grades of cancerous lesions using the 2 statistical methods of logistic regression with fixed effects and classic meta-analysis. The comparison of UUT cancer recurrence in patients with G1 vs G2 tumors using logistic regression with fixed effects showed an OR of (p ). This result was also confirmed by the second analysis, classic meta-analysis (OR 7.25, p 0.03, fig. 1, 1). These data reveal a statistically significant difference in recurrence for G1 vs G2. When comparing G1 and G3, there was a tendency in the difference between the incidence of G1 and G3 (fig. 1, 2). The comparison between patients with G2 and G3 bladder cancer was not significant (fig. 1, 3). The difference in G1-G2 vs G3 was also not significant (fig. 1, 4). Ultimately the comparison of G1 vs G2 associated to G3 showed a strong significant difference (fig. 1, 5). These data show that patients treated with radical cystectomy for low grade tumors have a greater propensity for a secondary lesion to develop in the UUT during followup. The relationship between low grade disease and late upper tract recurrence can be explained in 2 ways. 1) These patients are often affected by plurifocal and plurirecurrent TCC (not under control by simple transurethral resection). 2) These lesions are at high risk for extravesical urothelial involvement, and patients with low grade tumors have a potential long-term survival and followup. Disease Staging In this meta-analysis bladder cancer staging was as CIS, and superficial and muscle invasive tumors. In the comparison of UUT cancer recurrence in patients with superficial vs invasive tumors using logistic regression with fixed effects, the data indicated a statistically significant difference in recurrence in superficial vs invasive disease (fig. 1, 6). When comparing the recurrence rate in patients who underwent radical cystectomy for CIS vs superficial and invasive lesions, the data showed a statistically significant difference in recurrence for superficial vs invasive lesions and a strong significant difference in recurrence for CIS vs invasive lesions (fig. 1, 7 and fig. 2, 8).

4 UPPER URINARY TRACT RECURRENCE FOLLOWING RADICAL CYSTECTOMY 2049 Figure 1. Forrest and funnel plot of meta-analysis. Fixed or random effect was applied according to heterogeneity. In funnel plot vertical line represents OR estimate and oblique lines define region free from publication bias.

5 2050 UPPER URINARY TRACT RECURRENCE FOLLOWING RADICAL CYSTECTOMY Figure 2. Forrest and funnel plot of meta-analysis. Fixed or random effect was applied according to heterogeneity. In funnel plot vertical line represents OR estimate and oblique lines define region free from publication bias. UUTC, upper urinary tract cancer.

6 UPPER URINARY TRACT RECURRENCE FOLLOWING RADICAL CYSTECTOMY 2051 Patients who underwent cystectomy for CIS and superficial tumors had a high risk of UUT recurrence during followup compared to those with invasive lesions. The relationship between low stage and late upper tract recurrence can be explained in 2 ways. 1) Patients with CIS or superficial tumors are those with potential long-term followup. 2) These patients with recurrent multifocal superficial tumors or associated bladder CIS are at high risk for extravesical urothelial involvement. History or Concomitant Presence of CIS The classification of concomitant CIS or history of CIS includes foci of CIS concomitant to invasive or superficial lesions at cystectomy or history of a CIS lesion at prior transurethral resection. In the comparison of UUT cancer relapse in patients with a history of or with concomitant CIS vs the absence of CIS, the data do not support a statistically significant difference in recurrence (fig. 2, 9). Node Staging The comparison of N0 vs N (including all patients with lymph node involvement by the urothelial lesion) shows a strong significant difference in incidence (fig. 2, 10). Patients with nodal involvement have potential short-term followup related to their high mortality rate. Recurrent, Solitary or Multifocal Disease Data show a statistically significant difference in recurrence in patients with a history of multiple urothelial recurrences or with multifocal disease compared to those with a solitary lesion at precystectomy transurethral resection (fig. 2, 11). Ureteral Margin Status The comparison of UUT cancer recurrence in patients with positive vs negative ureteral margins using logistic regression with fixed effects showed an OR of (p ). This result was also confirmed but underestimated using classic meta-analysis (OR 3.28, p , fig. 2, 12). These data show a strong statistically significant difference in recurrence in patients with positive ureteral margins at cystectomy. Intraoperative analysis of ureteral margins via frozen sections at cystectomy before urinary tract reconstruction has long been accepted as a standard practice. The apparent rationale for such a procedure is that carcinoma, particularly carcinoma in situ, may involve the distal ureteral margin. Using frozen section analysis, surgeons can resect additional ureteral tissue to obtain an uninvolved ureteral margin, hopefully improving cancer control with complete tumor excision and decreasing the likelihood of disease recurrence. The actual usefulness of routine frozen section analysis before reconstruction of the ureterointestinal anastomosis has not been clearly proven. Doubt has been based on factors such as the limited ability of frozen section analysis to accurately identify ureteral malignancy, the fact that sequential resection does not definitively eliminate malignancy and the questionable effect of a malignant ureteral anastomotic margin on oncologic recurrence. With these data of strong statistical difference, we can delineate a risk class of patients who need accurate followup related to UUT recurrence, which constitutes a point in favor of this practice. Urethral Involvement Unfortunately, most studies do not differentiate between cases with direct extension of the prostate stroma by bladder tumor (pt4) and noncontiguous urothelial cancer involving the prostatic urethra. Considering these 2 possibilities as a single entity in the interpretation of urethral margin status, in the comparison of UUT recurrence with involvement of the urethral margins vs negative cases, the data show a strong statistically significant difference in recurrence (fig. 2, 13). The true incidence of eventual UUT tumor in those patients with urothelial tract cancer involving the prostatic urethra is unknown, with only 2 reports showing a statistically significant association. 18,22 Taking into consideration these 2 studies, in the comparison of UUT cancer recurrence using classic meta-analysis we found an OR of 7.19 with p These data show a stronger statistically significant difference in recurrence in patients with TCC of the male prostatic urethra or female urethra at cystectomy. Sved et al noted that superficial prostatic transitional cell disease was strongly associated with an increased risk of recurrence, whereas prostatic stromal invasion was not. 21 Sanderson et al identified superficial prostatic TCC as the only pathological variable in men significantly associated with an increased rate of UUT recurrence, and their data indicated that at 10 years men with prostatic urethral involvement were at a fourfold increased cumulative risk. 25 The lower rate of UUT recurrence in men with invasive prostatic pt4 disease is likely the result of significantly decreased survival and, thus, a shorter time at risk for recurrence. Supporting this hypothesis is the observation of Sved et al that the median survival of men with invasive prostatic TCC was significantly shorter than that of men with superficial prostatic TCC, and shorter than the median time for UUT to recur. 21 Urinary Diversion Type Urinary diversion was categorized as neobladder, continent stoma, ileal stoma, ureterosigmoidostomy and ureterocutaneostomy. No differences were

7 2052 UPPER URINARY TRACT RECURRENCE FOLLOWING RADICAL CYSTECTOMY found by logistic regression with fixed effects and classic meta-analysis. The cohort of patients treated with a neobladder had a favorable prognosis compared to those treated with other diversions. This finding was reflected in the better overall survival, which was mainly related to age and underlying comorbidities. Likewise, due to a higher proportion of organ confined tumors, disease specific survival was also superior in the neobladder group. Such inevitable selection bias in these methods of diversion must be considered when drawing conclusions related to cancer control, but we did not observe an increased risk of UUT recurrence in the various cohorts. History of UUT Urothelial Cancer The comparison of UUT recurrence in patients with vs without a history of UUT-TCC using classic metaanalysis revealed an OR of 7.25 with p 0.03 (fig. 2, 14). These data show a statistically significant difference in patients already treated for UUT cancer. Evaluation of Recurrence by Followup Method Due to clinical improvements in the detection and treatment of organ confined bladder cancer, in recent years many patients have had a favorable longterm prognosis. However, the optimum surveillance of UUT recurrence after cystectomy is controversial. The followup protocols vary in terms of timing and investigations. Three studies did not specify the type of followup. 7,15,32 In the other studies the followup schedule included radiological assessment of the UUT with loopgraphy, urography or computerized tomography. 1,8 14,16 31 In 18 of the 25 studies a periodic evaluation of urinary cytology was performed, 1,8,11,12,14,16,19 27,29 31 while in 2 it was performed only on the finding of radiological abnormalities due to hematuria and irritative symptoms. 9,13 One of the aims of regular followup is to increase the likelihood of the early detection of any subsequent upper tract tumor, enabling treatment at a curable stage. From the literature analysis 13 studies reported that recurrence was identified during the followup investigations or in response to symptoms suggestive of recurrence. 1,10,12 14,16 18,21,23,25,26,31 In 58 of 161 patients (38%) UUT recurrence was diagnosed by followup investigation and the majority of recurrence was diagnosed by symptoms in the remaining 62% of the cases. In 9 studies including 100 cases of recurrence (28 of which were identified by followup investigation), 66 described symptoms indicating a UUT lesion. 1,10,13,14,17,21,23,25,31 These included 46 cases with hematuria (60.5%), 19 with back pain and hydronephrosis (25%), 2 with fever (2.6%), 2 with weight loss (2.6%) and 1 with pyelonephritis (1.3%). In the remaining 4 cases the symptoms were unknown and in 2 the diagnosis of recurrence was incidental. Cytology In 9 studies 112 patients with recurrence, of whom 38 were identified at followup, positive urine cytology suggested the presence of an upper tract lesion in 10. 1,12,14,16,21,23,25,26,31 When urine cytology was used in the surveillance of patients after radical cystectomy, the rate of primary detection was 8.9%. There are many points of view on the usefulness of urinary cytology. It is an easy and noninvasive examination method for detecting tumors of the upper and/or lower urinary tract including the urethra. The incidence of UUT recurrence after radical cystectomy was extremely low, and it was somewhat difficult to interpret the urine cytology obtained from the diverted urinary tract. The urine excreted through the intestinal urinary diversion is different from normally voided urine, and it contains many degenerating desquamated intestinal epithelial cells that could obscure or be confused with cancer cells. Furthermore, the urine voided through a continent reservoir or an orthotopic neobladder usually stagnates for a few hours in the isolated intestine or the colon, which also allows the urinary cells to degenerate. In addition, urine cytology itself depends to some extent on cytopathologist ability/experience. Nevertheless, some authors argue that cytology is an inexpensive way to monitor the urinary tract for TCC and, since most UUT cancers after cystectomy are reported to be high grade, the sensitivity of cytology should accordingly be high. Based on this analysis the incidence of UUT-TCC was extremely low and the interpretation of urine cytology from the diverted urinary tract was somewhat difficult. Therefore, frequent routine urine cytology examinations might yield insufficient benefit if not restricted to high risk patients. In fact, in 9 studies 4,616 patients underwent routine cytological examination (2 to 4 times in the first years) to identify 10 of 112 patients with recurrence (2.1/1,000). 1,12,14,16,21,23,25,26,31 Thus, approximately 2,000 urinary cytology examinations were performed to identify 1 patient with UUT recurrence. UUT Imaging In 13 studies on 161 patients of whom 58 were identified at followup, radiological findings suggested the presence of an upper tract lesion in 40 patients. 1,9,10,12 14,16 18,21,23,25,26,31 When UUT imaging was used in the surveillance of patients after radical cystectomy, the rate of primary detection was 24.8%. The value of urography in the detection of UUT recurrence after radical cystectomy is controversial. Some groups consider these regular investigations a necessity, while others maintain the opposite based

8 UPPER URINARY TRACT RECURRENCE FOLLOWING RADICAL CYSTECTOMY 2053 on the low yield of UUT imaging, the fact that the outcome does not appear to improve and that this examination lost information regarding the status of secondary lesions in parenchymal organs and bones. This renders regular urography examinations for followup in all patients after cystectomy hardly defensible. It has been estimated that 5,885 patients underwent routine UUT imaging to identify 40 of 161 patients with recurrence (6.7/1,000). Thus, approximately 800 radiological examinations were performed to identify 1 patient with UUT recurrence. 1,9,11 14,16 18,21,23,25,26,31 It is impossible to define the sensitivity and specificity of a single radiological procedure. We can emphasize that the use of computerized tomography with urography combines the ability to study the upper urinary tract oncologically and functionally for the identification of any parenchymal, osseous or lymph node secondary lesion. Evaluation of Treatment In 16 articles the possibility of undergoing surgical intervention was reported, and from these data of 218 patients 175 underwent surgery, 38 presented with characteristics of inoperability and 5 refused therapy. 8 10,12,14,15,18 21,24 26,28,29,31 In several studies the operability of the patients was reported along with the surgical procedure. 9,10,12,14 26,28,29,31 Of 193 patients 165 underwent nephroureterectomy, 23 tumorectomy (1 of whom then underwent nephroureterectomy) and 5 ureterotomy (bilateral in 1). Analysis and Outcome of Recurrence Recurrence varied during followup with a range of 2.4 to 174 months. 8,10,12 14,16 18,21 27,29 31 In analyzing the recurrences, most tumors were only detected in an advanced (41 noninvasive lesions compared to 93 negative nodes in 13 studies) or metastatic state (16 lymph node metastases compared to 29 negative nodes in 13 studies), which is reflected in the poor survival rates (74 survived vs 127 deceased in 17 studies during the 1 to 120-month interval of discovery of UUT recurrence to death). 8 10,12,14,15,18 21,24 26,28,29,31 We could not detect a relevant survival advantage in patients in whom the tumor was diagnosed by followup studies compared to those in whom symptoms led to the diagnosis because the data are poor. Potential Flaws Potentials flaws of these meta-analyses involve the retrospective nature of some of the included studies, the different protocols of followup adopted with their varying ability to reveal UUT-TCC recurrence, the progress in the surgical and imaging studies that was made since the 1970s and, in the end, the different adjuvant protocols adopted. CONCLUSIONS After reading this article most investigators would agree that there is a subset of patients at higher risk for recurrence who might benefit from more diligent upper tract surveillance after cystectomy. Early detection of recurrent disease results in the timely administration of appropriate therapy and potentially improves patient outcomes. Based on cystectomy specimens and patient urological history, we can delineate risk factors for UUT recurrence and weigh each of these in every single patient. Patients with a G1 tumor have an 8 times greater probability of a UUT-TCC lesion compared to those with G2 cancer, and a probability 10 times higher than those with G3 disease. Patients with CIS have a probability of a UUT-TCC lesion twice as high as those with superficial cancer, and a probability 4 times higher than those with invasive disease. Patients with superficial cancer have a probability of a UUT-TCC lesion twice as high as those with invasive disease. Multifocality increases the risk of recurrence of 3 times and recurrence from 2 to 4 times. Positive ureteral or urethral margins increase the risk sevenfold. The same increase in risk is present in patients with a history of UUT urothelial cancer. Patients with a negative node status have a risk increased eightfold. The extensive followup for the detection of upper tract recurrence based on cytology and excretory urography is ineffective and expensive. Cytology would be eliminated in the routine followup and urography would need to be substituted by computerized tomography to unite the oncologic study of the upper urinary tract, the abdominal organs and lymph nodes in the functional study of the new modified urinary diversion. REFERENCES 1. Volkmer BG, Schnoeller T, Kuefer R et al: Upper urinary tract recurrence after radical cystectomy for bladder cancer who is at risk? J Urol 2009; 182: AUA Bladder Cancer Clinical Guideline Update Panel: Guideline for the Management of Nonmuscle Invasive Bladder Cancer: (Stages Ta, T1, and Tis): 2007 Update. Available at clinical-practice-guidelines/clinical-guidelines.cfm? sub bc. Accessed August 3, EAU Guidelines 2011: Bladder Cancer Muscleinvasive and Metastatic. 4. Harris RP, Helfand M, Woolf SH et al: Current methods of the US Preventive Services Task Force: a review of the process. Am J Prev Med 2001; 20: Harris R, Atkins D, Berg AO et al: US Preventive Services Task Force Procedure Manual. Rockville: Agency for Healthcare Research and Quality 2001.

9 2054 UPPER URINARY TRACT RECURRENCE FOLLOWING RADICAL CYSTECTOMY 6. Moher D, Liberati A, Tetzlaff J et al: Preferred reporting items for systematic reviews and metaanalyses: the PRISMA statement. PLoS Med 2009; 6: e Schellhammer PF and Whitmore WF Jr: Transitional cell carcinoma of the urethra in men having cystectomy for bladder cancer. J Urol 1976; 115: Zincke H, Garbeff PJ and Beahrs JR: Upper urinary tract transitional cell cancer after radical cystectomy for bladder cancer. J Urol 1984; 131: Malkowicz SB and Skinner DG: Development of upper tract carcinoma after cystectomy for bladder carcinoma. Urology 1990; 36: Hastie KJ, Hamdy FC, Collins MC et al: Upper tract tumours following cystectomy for bladder cancer. Is routine intravenous urography worthwhile? Br J Urol 1991; 67: Schwartz CB, Bekirov H and Melman A: Urothelial tumors of upper tract following treatment of primary bladder transitional cell carcinoma. Urology 1992; 40: Kenworthy P, Tanguay S and Dinney CP: The risk of upper tract recurrence following cystectomy in patients with transitional cell carcinoma involving the distal ureter. J Urol 1996; 155: Tsuji Y, Nakamura H and Ariyoshi A: Upper urinary tract involvement after cystectomy and ileal conduit diversion for primary bladder carcinoma. Eur Urol 1996; 29: Silver DA, Stroumbakis N, Russo P et al: Ureteral carcinoma in situ at radical cystectomy: does the margin matter? J Urol 1997; 158: Studer UE and Zingg EJ: Ileal orthotopic bladder substitutes. What we have learned from 12 years experience with 200 patients. Urol Clin North Am 1997; 24: Balaji KC, McGuire M, Grotas J et al: Upper tract recurrences following radical cystectomy: an analysis of prognostic factors, recurrence pattern and stage at presentation. J Urol 1999; 162: Slaton JW, Swanson DA, Grossman HB et al: A stage specific approach to tumor surveillance after radical cystectomy for transitional cell carcinoma of the bladder. J Urol 1999; 162: Huguet-Pérez J, Palou J, Millán-Rodríguez F et al: Upper tract transitional cell carcinoma following cystectomy for bladder cancer. Eur Urol 2001; 40: Solsona E, Iborra I, Rubio J et al: Late oncological occurrences following radical cystectomy in patients with bladder cancer. Eur Urol 2003; 43: Yossepowitch O, Dalbagni G, Golijanin D et al: Orthotopic urinary diversion after cystectomy for bladder cancer: implications for cancer control and patterns of disease recurrence. J Urol 2003; 169: Sved PD, Gomez P, Nieder AM et al: Upper tract tumour after radical cystectomy for transitional cell carcinoma of the bladder: incidence and risk factors. BJU Int 2004; 94: Lee SE, Byun SS, Hong SK et al: Significance of cancer involvement at the ureteral margin detected on routine frozen section analysis during radical cystectomy. Urol Int 2006; 77: Akkad T, Gozzi C, Deibl M et al: Tumor recurrence in the remnant urothelium of females undergoing radical cystectomy for transitional cell carcinoma of the bladder: long-term results from a single center. J Urol 2006; 175: Furukawa J, Miyake H, Hara I et al: Upper urinary tract recurrence following radical cystectomy for bladder cancer. Int J Urol 2007; 14: Sanderson KM, Cai J, Miranda G et al: Upper tract urothelial recurrence following radical cystectomy for transitional cell carcinoma of the bladder: an analysis of 1,069 patients with 10-year followup. J Urol 2007; 177: Meissner C, Giannarini G, Schumacher MC et al: The efficiency of excretory urography to detect upper urinary tract tumors after cystectomy for urothelial cancer. J Urol 2007; 178: Tran W, Serio AM, Raj GV et al: Longitudinal risk of upper tract recurrence following radical cystectomy for urothelial cancer and the potential implications for long-term surveillance. J Urol 2008; 179: Boström PJ, Mirtti T, Kössi J et al: Twenty-year experience of radical cystectomy for bladder cancer in a medium-volume centre. Scand J Urol Nephrol 2009; 43: Tollefson MK, Blute ML, Farmer SA et al: Significance of distal ureteral margin at radical cystectomy for urothelial carcinoma. J Urol 2010; 183: Umbreit EC, Crispen PL, Shimko MS et al: Multifactorial, site-specific recurrence model after radical cystectomy for urothelial carcinoma. Cancer 2010; 116: Yoshimine S, Kikuchi E, Matsumoto K et al: The clinical significance of urine cytology after a radical cystectomy for urothelial cancer. Int J Urol 2010; 17: Gakis G, Schilling D, Perner S et al: Sequential resection of malignant ureteral margins at radical cystectomy: a critical assessment of the value of frozen section analysis. World J Urol 2011; 29: Lindsey JK: On the use of corrections for overdispersion. J R Stat Soc Ser C Appl Stat 1999; 48: DerSimonian R and Laird N: Meta-analysis in clinical trials. Control Clin Trials 1986; 7: Harbord RM, Egger M and Sterne JA: A modified test for small-study effects in meta-analyses of controlled trials with binary endpoints. Stat Med 2006; 25: 3443.

Multiple factor analysis of metachronous upper urinary tract transitional cell carcinoma after radical cystectomy

Multiple factor analysis of metachronous upper urinary tract transitional cell carcinoma after radical cystectomy Brazilian Journal of Medical and Biological Research (2007) 40: 979-984 Predictive factors after radical cystectomy ISSN 0100-879X 979 Multiple factor analysis of metachronous upper urinary tract transitional

More information

TCC recurrence within the upper tract urothelium following

TCC recurrence within the upper tract urothelium following Upper Tract Urothelial Recurrence Following Radical Cystectomy for Transitional Cell Carcinoma of the Bladder: An Analysis of 1,069 Patients With 10-Year Followup Kristin M. Sanderson,* Jie Cai, Gustavo

More information

Haijun Zhou, Jae Y Ro, Luan D Truong, Alberto G Ayala, Steven S Shen

Haijun Zhou, Jae Y Ro, Luan D Truong, Alberto G Ayala, Steven S Shen Am J Clin Exp Urol 2014;2(2):156-160 www.ajceu.us /ISSN:2330-1910/AJCEU0000048 Original Article Intraoperative frozen section evaluation of ureteral and urethral margins: studies of 203 consecutive radical

More information

MUSCLE-INVASIVE AND METASTATIC BLADDER CANCER

MUSCLE-INVASIVE AND METASTATIC BLADDER CANCER MUSCLE-INVASIVE AND METASTATIC BLADDER CANCER (Text update March 2008) A. Stenzl (chairman), N.C. Cowan, M. De Santis, G. Jakse, M. Kuczyk, A.S. Merseburger, M.J. Ribal, A. Sherif, J.A. Witjes Introduction

More information

MUSCLE - INVASIVE AND METASTATIC BLADDER CANCER

MUSCLE - INVASIVE AND METASTATIC BLADDER CANCER 10 MUSCLE - INVASIVE AND METASTATIC BLADDER CANCER Recommendations from the EAU Working Party on Muscle Invasive and Metastatic Bladder Cancer G. Jakse (chairman), F. Algaba, S. Fossa, A. Stenzl, C. Sternberg

More information

GUIDELINES ON NON-MUSCLE- INVASIVE BLADDER CANCER

GUIDELINES ON NON-MUSCLE- INVASIVE BLADDER CANCER GUIDELINES ON NON-MUSCLE- INVASIVE BLADDER CANCER (Limited text update December 21) M. Babjuk, W. Oosterlinck, R. Sylvester, E. Kaasinen, A. Böhle, J. Palou, M. Rouprêt Eur Urol 211 Apr;59(4):584-94 Introduction

More information

Koji Ichihara Hiroshi Kitamura Naoya Masumori Fumimasa Fukuta Taiji Tsukamoto

Koji Ichihara Hiroshi Kitamura Naoya Masumori Fumimasa Fukuta Taiji Tsukamoto Int J Clin Oncol (2013) 18:75 80 DOI 10.1007/s10147-011-0346-8 ORIGINAL ARTICLE Transurethral prostate biopsy before radical cystectomy remains clinically relevant for decision-making on urethrectomy in

More information

Radical Cystectomy Often Too Late? Yes, But...

Radical Cystectomy Often Too Late? Yes, But... european urology 50 (2006) 1129 1138 available at www.sciencedirect.com journal homepage: www.europeanurology.com Editorial 50th Anniversary Radical Cystectomy Often Too Late? Yes, But... Urs E. Studer

More information

BLADDER CANCER: PATIENT INFORMATION

BLADDER CANCER: PATIENT INFORMATION BLADDER CANCER: PATIENT INFORMATION The bladder is the balloon like organ located in the pelvis that stores and empties urine. Urine is produced by the kidneys, is conducted to the bladder by the ureters,

More information

Optimal Timing of Radical Cystectomy for Patients with Invasive Transitional Cell Carcinoma of the Bladder

Optimal Timing of Radical Cystectomy for Patients with Invasive Transitional Cell Carcinoma of the Bladder Jpn J Clin Oncol 2002;32(1)14 18 Optimal Timing of Radical Cystectomy for Patients with Invasive Transitional Cell Carcinoma of the Bladder Isao Hara, Hideaki Miyake, Shoji Hara, Akinobu Gotoh, Hiroshi

More information

Bladder Cancer Guidelines

Bladder Cancer Guidelines Bladder Cancer Guidelines Agreed by Urology CSG: October 2011 Review Date: September 2013 Bladder Cancer 1. Referral Guidelines The following patients should be considered as potentially having bladder

More information

Upper urinary tract urothelial cell carcinoma: location as a predictive factor for concomitant bladder carcinoma

Upper urinary tract urothelial cell carcinoma: location as a predictive factor for concomitant bladder carcinoma DOI 10.1007/s00345-012-0877-2 ORIGINAL ARTICLE Upper urinary tract urothelial cell carcinoma: location as a predictive factor for concomitant bladder carcinoma Marco Cosentino Joan Palou Josep M. Gaya

More information

Carcinoma of the Urinary Bladder Histopathology

Carcinoma of the Urinary Bladder Histopathology Carcinoma of the Urinary Bladder Histopathology Reporting Proforma (Radical & Partial Cystectomy, Cystoprostatectomy) Includes the International Collaboration on Cancer reporting dataset denoted by * Family

More information

Citation International journal of urology (2. Right which has been published in final f

Citation International journal of urology (2.  Right which has been published in final f Title Novel constant-pressure irrigation of renal pelvic tumors after ipsila Nakamura, Kenji; Terada, Naoki; Sug Author(s) Toshinori; Matsui, Yoshiyuki; Imamu Kazutoshi; Kamba, Tomomi; Yoshimura Citation

More information

Radical Cystectomy in the Treatment of Bladder Cancer: Oncological Outcome and Survival Predictors

Radical Cystectomy in the Treatment of Bladder Cancer: Oncological Outcome and Survival Predictors ORIGINAL ARTICLE Radical Cystectomy in the Treatment of Bladder Cancer: Oncological Outcome and Survival Predictors Chen-Hsun Ho, 1,2 Chao-Yuan Huang, 1 Wei-Chou Lin, 3 Shih-Chieh Chueh, 1 Yeong-Shiau

More information

Diagnosis and classification

Diagnosis and classification Patient Information English 2 Diagnosis and classification The underlined terms are listed in the glossary. Signs and symptoms Blood in the urine is the most common symptom when a bladder tumour is present.

More information

Multiple Primary and Histology Site Specific Coding Rules URINARY. FLORIDA CANCER DATA SYSTEM MPH Urinary Site Specific Coding Rules

Multiple Primary and Histology Site Specific Coding Rules URINARY. FLORIDA CANCER DATA SYSTEM MPH Urinary Site Specific Coding Rules Multiple Primary and Histology Site Specific Coding Rules URINARY 1 Prerequisites 2 Completion of Multiple Primary and Histology General Coding Rules 3 There are many ways to view the Multiple l Primary/Histology

More information

Staging and Grading Last Updated Friday, 14 November 2008

Staging and Grading Last Updated Friday, 14 November 2008 Staging and Grading Last Updated Friday, 14 November 2008 There is a staging graph below Blood in the urine is the most common indication that something is wrong. Often one will experience pain or difficulty

More information

Q&A. Fabulous Prizes. Collecting Cancer Data: Bladder, Renal Pelvis, and Ureter 5/2/13. NAACCR Webinar Series

Q&A. Fabulous Prizes. Collecting Cancer Data: Bladder, Renal Pelvis, and Ureter 5/2/13. NAACCR Webinar Series Collecting Cancer Data Bladder & Renal Pelvis NAACCR 2012 2013 Webinar Series Q&A Please submit all questions concerning webinar content through the Q&A panel. Reminder: If you have participants watching

More information

Long-Term Complications of Conduit Urinary Diversion

Long-Term Complications of Conduit Urinary Diversion Long-Term Complications of Conduit Urinary Diversion Mark S. Shimko,* Matthew K. Tollefson, Eric C. Umbreit, Sara A. Farmer, Michael L. Blute and Igor Frank From the Department of Urology (MSS, MKT, ECU,

More information

REVIEW. Patterns of recurrence of bladder carcinoma following radical cystectomy

REVIEW. Patterns of recurrence of bladder carcinoma following radical cystectomy Cancer Imaging (2003) 3, 96 100 DOI: 10.1102/1470-7330.2003.0009 CI REVIEW Patterns of recurrence of bladder carcinoma following radical cystectomy D M Koh and J E Husband Academic Department of Radiology,

More information

When to Integrate Surgery for Metatstatic Urothelial Cancers

When to Integrate Surgery for Metatstatic Urothelial Cancers When to Integrate Surgery for Metatstatic Urothelial Cancers Wade J. Sexton, M.D. Senior Member and Professor Department of Genitourinary Oncology Moffitt Cancer Center Case Presentation #1 67 yo male

More information

The Predictors of Local Recurrence after Radical Cystectomy in Patients with Invasive Bladder Cancer

The Predictors of Local Recurrence after Radical Cystectomy in Patients with Invasive Bladder Cancer The Predictors of Local Recurrence after Radical Cystectomy in Patients with Invasive Bladder Cancer Hiroki Ide, Eiji Kikuchi, Akira Miyajima, Ken Nakagawa, Takashi Ohigashi, Jun Nakashima and Mototsugu

More information

Joseph H. Williams, MD Idaho Urologic Institute St. Alphonsus Regional Medical Center September 22, 2016

Joseph H. Williams, MD Idaho Urologic Institute St. Alphonsus Regional Medical Center September 22, 2016 BLADDER CANCER Joseph H. Williams, MD Idaho Urologic Institute St. Alphonsus Regional Medical Center September 22, 2016 BLADDER CANCER = UROTHELIAL CANCER Antiquated term is Transitional Cell Carcinoma

More information

RITE Thermochemotherapy in the treatment of BCG refractory NMIBC

RITE Thermochemotherapy in the treatment of BCG refractory NMIBC RITE Thermochemotherapy in the treatment of BCG refractory NMIBC Ben Ayres Consultant Urological Surgeon St George s Hospital London 1 Financial and Other Disclosures Off-label use of drugs, devices, or

More information

NMIBC. Piotr Jarzemski. Department of Urology Jan Biziel University Hospital Bydgoszcz, Poland

NMIBC. Piotr Jarzemski. Department of Urology Jan Biziel University Hospital Bydgoszcz, Poland NMIBC Piotr Jarzemski Department of Urology Jan Biziel University Hospital Bydgoszcz, Poland 71 year old male patient was admitted to the Department of Urology First TURBT - 2 months prior to the hospitalisation.

More information

Index. Surg Oncol Clin N Am 14 (2005) Note: Page numbers of article titles are in boldface type.

Index. Surg Oncol Clin N Am 14 (2005) Note: Page numbers of article titles are in boldface type. Surg Oncol Clin N Am 14 (2005) 433 439 Index Note: Page numbers of article titles are in boldface type. A Abdominosacral resection, of recurrent rectal cancer, 202 215 Ablative techniques, image-guided,

More information

Symptoms, Diagnosis and Classification

Symptoms, Diagnosis and Classification Patient Information English 2 Symptoms, Diagnosis and Classification The underlined terms are listed in the glossary. Signs and symptoms Blood in the urine is the most common symptom when a bladder tumour

More information

International Journal of Health Sciences and Research ISSN:

International Journal of Health Sciences and Research   ISSN: International Journal of Health Sciences and Research www.ijhsr.org ISSN: 2249-9571 Original Research Article Outcome of Open Radical Cystectomy and Ileal Conduit: A Single Center Experience Mahesh Kalloli

More information

Ureteral orifice involvement by urothelial carcinoma: long term oncologic and functional outcomes

Ureteral orifice involvement by urothelial carcinoma: long term oncologic and functional outcomes ORIGINAL ARTICLE Vol. 43 (x): 2017 August 8.[Ahead of print] doi: 10.1590/S1677-5538.IBJU.2017.0218 Ureteral orifice involvement by urothelial carcinoma: long term oncologic and functional outcomes Muammer

More information

The Efficacy of Adjuvant Chemotherapy for Locally Advanced Upper Tract Urothelial Cell Carcinoma

The Efficacy of Adjuvant Chemotherapy for Locally Advanced Upper Tract Urothelial Cell Carcinoma Ivyspring International Publisher Research Paper 686 Journal of Cancer 2013; 4(8): 686-690. doi: 10.7150/jca.7326 The Efficacy of Adjuvant Chemotherapy for Locally Advanced Upper Tract Urothelial Cell

More information

UROTHELIAL CELL CANCER

UROTHELIAL CELL CANCER UROTHELIAL CELL CANCER Indications and regimens for neoadjuvant systemic treatment Astrid A. M. van der Veldt, MD, PhD, medical oncologist Department of Medical Oncology Erasmus Medical Center Cancer Institute

More information

Does the Use of Angiotensin-Converting Enzyme Inhibitors or Angiotensin II Receptor Blockers Improve Survival in Bladder Cancer?

Does the Use of Angiotensin-Converting Enzyme Inhibitors or Angiotensin II Receptor Blockers Improve Survival in Bladder Cancer? Does the Use of Angiotensin-Converting Enzyme Inhibitors or Angiotensin II Receptor Blockers Improve Survival in Bladder Cancer? Authors: Roderick Clark, 1 Kevin Wong, 2 Stacy Fan, 2 Joseph Chin, 1,3 Jonathan

More information

Neo-adjuvant chemotherapy and bladder preservation in locally advanced transitional cell carcinoma of the bladder

Neo-adjuvant chemotherapy and bladder preservation in locally advanced transitional cell carcinoma of the bladder Annals of Oncology : -5. 999. 999 Klimer Academic Publishers. Printed in the Netherlands. Original article Neo-adjuvant chemotherapy and bladder preservation in locally advanced transitional cell carcinoma

More information

Anterior urethra sparing cystoprostatectomy for bladder cancer: a 10 year, single center experience

Anterior urethra sparing cystoprostatectomy for bladder cancer: a 10 year, single center experience DOI 10.1186/s40064-015-1200-7 RESEARCH Open Access Anterior urethra sparing cystoprostatectomy for bladder cancer: a 10 year, single center experience Nozomi Hayakawa 1,2*, Nobuyuki Kikuno 1,2, Hiroki

More information

Attachment #2 Overview of Follow-up

Attachment #2 Overview of Follow-up Attachment #2 Overview of Follow-up Provided below is a general overview of follow-up and this may vary based on specific patient or cancer characteristics. Of note, Labs and imaging can be performed closer

More information

Bricker versus Wallace anastomosis: A meta-analysis of ureteroenteric stricture rates after ileal conduit urinary diversion

Bricker versus Wallace anastomosis: A meta-analysis of ureteroenteric stricture rates after ileal conduit urinary diversion Original research Bricker versus Wallace anastomosis: A meta-analysis of ureteroenteric stricture rates after ileal conduit urinary diversion Niall F. Davis, MD; John P. Burke, MD; TED McDermott, MD; Robert

More information

Attachment #2 Overview of Follow-up

Attachment #2 Overview of Follow-up Attachment #2 Overview of Follow-up Provided below is a general overview of follow-up and this may vary based on specific patient or cancer characteristics. Of note, Labs and imaging can be performed closer

More information

1. Introduction. 2. Methods. high-risk NMIBC in men with and without a prior history of RT for PC.

1. Introduction. 2. Methods. high-risk NMIBC in men with and without a prior history of RT for PC. ISRN Urology Volume 2013, Article ID 405064, 5 pages http://dx.doi.org/10.1155/2013/405064 Research Article Radical Cystectomy after BCG Immunotherapy for High-Risk Nonmuscle-Invasive Bladder Cancer in

More information

Clinical significance of immediate urine cytology after transurethral resection of bladder tumor in patients with non-muscle invasive bladder cancer

Clinical significance of immediate urine cytology after transurethral resection of bladder tumor in patients with non-muscle invasive bladder cancer International Journal of Urology (2011) 18, 439 443 doi: 10.1111/j.1442-2042.2011.02766.x Original Article: Clinical Investigationiju_2766 439..443 Clinical significance of immediate urine cytology after

More information

The Effects of Intravesical Chemoimmunotherapy with Gemcitabine and Bacillus Calmette Guérin in Superficial Bladder Cancer: a Preliminary Study

The Effects of Intravesical Chemoimmunotherapy with Gemcitabine and Bacillus Calmette Guérin in Superficial Bladder Cancer: a Preliminary Study The Journal of International Medical Research 2009; 37: 1823 1830 The Effects of Intravesical Chemoimmunotherapy with Gemcitabine and Bacillus Calmette Guérin in Superficial Bladder Cancer: a Preliminary

More information

Bladder Case 1 SURGICAL PATHOLOGY REPORT. Procedure: Cystoscopy, transurethral resection of bladder tumor (TURBT)

Bladder Case 1 SURGICAL PATHOLOGY REPORT. Procedure: Cystoscopy, transurethral resection of bladder tumor (TURBT) Bladder Case 1 February 17, 2007 Specimen (s) received: Bladder Tumor Pre-operative Diagnosis: Bladder Cancer Post operative Diagnosis: Bladder Cancer Procedure: Cystoscopy, transurethral resection of

More information

A Personal History NIH CWRU U of TN U of Miami Animal Model for Bladder Cancer Carcinogen induced FANFT Three Models Primary tumors individual tumors, simulates clinical scenario of locally advanced cancer

More information

INCIDENTAL PROSTATE CANCER IN PATIENTS UNDERGOING RADICAL CYSTOPROSTATECTOMY FOR BLADDER CANCER

INCIDENTAL PROSTATE CANCER IN PATIENTS UNDERGOING RADICAL CYSTOPROSTATECTOMY FOR BLADDER CANCER & INCIDENTAL PROSTATE CANCER IN PATIENTS UNDERGOING RADICAL CYSTOPROSTATECTOMY FOR BLADDER CANCER Mustafa Hiroš *, Hajrudin Spahović, Mirsad Selimović, Sabina Sadović Urology Clinic, University of Sarajevo

More information

Radical cystectomy is the standard procedure for the. rezime ...

Radical cystectomy is the standard procedure for the. rezime ... /STRU^NI RAD UDK 616.62-006.04-089.844 Local Recurrence of Bladder Cancer after Cystectomy with Orthotopic Bladder Substitution and Conduit... Pejcic T 1, Hadzi-Djokic J 1, Acimovic M 1, Markovic B 2,

More information

Clinical Study Ureteroscopic Laser Treatment of Upper Urinary Tract Urothelial Cell Carcinomas: Can a Tumour Free Status Be Achieved?

Clinical Study Ureteroscopic Laser Treatment of Upper Urinary Tract Urothelial Cell Carcinomas: Can a Tumour Free Status Be Achieved? Advances in Urology Volume 2013, Article ID 429585, 4 pages http://dx.doi.org/10.1155/2013/429585 Clinical Study Ureteroscopic Laser Treatment of Upper Urinary Tract Urothelial Cell Carcinomas: Can a Tumour

More information

Glossary of Terms Primary Urethral Cancer

Glossary of Terms Primary Urethral Cancer Patient Information English Glossary of Terms Primary Urethral Cancer Advanced cancer A tumour that grows into deeper layers of tissue, adjacent organs, or surrounding muscles. Anaesthesia (general, spinal,

More information

PROFESSIONAL SKILLS 1 3RD YEAR SEMESTER 6 RADIOGRAPHY. THE URINARY SYSTEM Uz. Fatema shmus aldeen Tel

PROFESSIONAL SKILLS 1 3RD YEAR SEMESTER 6 RADIOGRAPHY. THE URINARY SYSTEM Uz. Fatema shmus aldeen Tel PROFESSIONAL SKILLS 1 3RD YEAR SEMESTER 6 RADIOGRAPHY THE URINARY SYSTEM Uz. Fatema shmus aldeen Tel. 0925111552 Professional skills-2 THE URINARY SYSTEM The urinary system (review anatomy and physiology)

More information

Urological Tumours 1 Kidney tumours 2 Bladder tumours

Urological Tumours 1 Kidney tumours 2 Bladder tumours Urological Tumours 1 Kidney tumours 2 Bladder tumours Tim Bracey SpR Histopathology Derriford Hospital Kidney tumours What are we going to talk about?! Anatomy of urinary tract! Types of kidney tumours!

More information

Information for Patients. Bladder Cancer. English

Information for Patients. Bladder Cancer. English Information for Patients Bladder Cancer English Table of contents What is the function of the bladder?... 3 What is bladder cancer?... 3 What causes bladder cancer?... 3 Stages of the disease... 3 Risk

More information

Comparative Analysis of Stage and Other Prognostic Factors Among Urethral, Ureteral, and Renal Pelvis Malignant Tumors

Comparative Analysis of Stage and Other Prognostic Factors Among Urethral, Ureteral, and Renal Pelvis Malignant Tumors Comparative Analysis of Stage and Other Prognostic Factors Among Urethral, Ureteral, and Renal Pelvis Malignant Tumors Presented to NAACCR Annual Conference 2012 Serban Negoita, MD, DrPH; Marsha Dunn,

More information

INVASIVE BLADDER CANCER

INVASIVE BLADDER CANCER INVASIVE BLADDER CANCER - Aspects on staging and prognosis Liedberg, Fredrik 2006 Link to publication Citation for published version (APA): Liedberg, F. (2006). INVASIVE BLADDER CANCER - Aspects on staging

More information

EAU GUIDELINES ON NON-MUSCLE INVASIVE (TaT1, CIS) BLADDER CANCER

EAU GUIDELINES ON NON-MUSCLE INVASIVE (TaT1, CIS) BLADDER CANCER EU GUIDELINES ON NON-MUSLE INVSIVE (TaT1, IS) LDDER NER (Limited text update March 2017) M. abjuk (hair), M. urger (Vice-hair), E. ompérat, P. Gontero,.H. Mostafid, J. Palou,.W.G. van Rhijn, M. Rouprêt,

More information

Segmental ureterectomy does not compromise the oncologic outcome compared with nephroureterectomy for pure ureter cancer

Segmental ureterectomy does not compromise the oncologic outcome compared with nephroureterectomy for pure ureter cancer Int Urol Nephrol (2014) 46:921 926 DOI 10.1007/s11255-013-0514-z UROLOGY - ORIGINAL PAPER Segmental ureterectomy does not compromise the oncologic outcome compared with nephroureterectomy for pure ureter

More information

Muscle-invasive bladder cancer

Muscle-invasive bladder cancer Patient Information English 4 Muscle-invasive bladder cancer The underlined terms are listed in the glossary. What is muscle-invasive bladder cancer? About a quarter of patients diagnosed with bladder

More information

Reviewing Immunotherapy for Bladder Carcinoma In Situ

Reviewing Immunotherapy for Bladder Carcinoma In Situ Reviewing Immunotherapy for Bladder Carcinoma In Situ Samir Bidnur Dept of Urologic Sciences, Grand Rounds March 1 st, 2017 Checkpoint Inhibition and Bladder Cancer, an evolving story with immunotherapy

More information

Guidelines for the Management of Bladder Cancer West Midlands Expert Advisory Group for Urological Cancer

Guidelines for the Management of Bladder Cancer West Midlands Expert Advisory Group for Urological Cancer Guidelines for the Management of Bladder Cancer West Midlands Expert Advisory Group for Urological Cancer West Midlands Clinical Networks and Clinical Senate Coversheet for Network Expert Advisory Group

More information

Carcinoma of the Renal Pelvis and Ureter Histopathology

Carcinoma of the Renal Pelvis and Ureter Histopathology Carcinoma of the Renal Pelvis and Ureter Histopathology Reporting Proforma (NEPHROURETERECTOMY AND URETERECTOMY) Includes the International Collaboration on Cancer reporting dataset denoted by * Family

More information

Bladder replacement in men and women: when and when not? Outline. Continent Diversion History

Bladder replacement in men and women: when and when not? Outline. Continent Diversion History 1 Bladder replacement in men and women: when and when not? Eila C. Skinner, MD Professor of Clinical Urology Keck USC School of Medicine Outline 1) Selection criteria for orthotopic diversion: Tumor-related

More information

Dr. Tareq Salah Ahmed,MD,ESMO. Lecturer of clinical oncology, Assiut faculty of medicine ESMO accreditation certificate

Dr. Tareq Salah Ahmed,MD,ESMO. Lecturer of clinical oncology, Assiut faculty of medicine ESMO accreditation certificate Dr. Tareq Salah Ahmed,MD,ESMO Lecturer of clinical oncology, Assiut faculty of medicine ESMO accreditation certificate 1 st Assiut Urology department conference,marsa Alam 3 rd February 2015 Bladder cancer

More information

The Impact of Blue Light Cystoscopy with Hexaminolevulinate (HAL) on Progression of Bladder Cancer ANewAnalysis

The Impact of Blue Light Cystoscopy with Hexaminolevulinate (HAL) on Progression of Bladder Cancer ANewAnalysis Bladder Cancer 2 (2016) 273 278 DOI 10.3233/BLC-160048 IOS Press Research Report 273 The Impact of Blue Light Cystoscopy with Hexaminolevulinate (HAL) on Progression of Bladder Cancer ANewAnalysis Ashish

More information

ENDOSCOPIC URETERECTOMY DURING NEPHROURETERECTOMY FOR UPPER URINARY TRACT TRANSITIONAL CELL CARCINOMA

ENDOSCOPIC URETERECTOMY DURING NEPHROURETERECTOMY FOR UPPER URINARY TRACT TRANSITIONAL CELL CARCINOMA ENDOSCOPIC URETERECTOMY DURING NEPHROURETERECTOMY FOR UPPER URINARY TRACT TRANSITIONAL CELL CARCINOMA Il. Saltirov, Ts. Petkov, G. Georgiev, K.Petkova Department of Urology and Nephrology, Military Medical

More information

3.1 Investigations for Patients Presenting with Haematuria Table 1

3.1 Investigations for Patients Presenting with Haematuria Table 1 3.1 Investigations for Patients Presenting with Haematuria Table 1 Patients at risk of bacterial endocarditis should be given antibiotic prophylaxis as per local guidelines. Patients with heart valve replacements

More information

Clinical Study of G3 Superficial Bladder Cancer without Concomitant CIS Treated with Conservative Therapy

Clinical Study of G3 Superficial Bladder Cancer without Concomitant CIS Treated with Conservative Therapy Jpn J Clin Oncol 2002;32(11)461 465 Clinical Study of G3 Superficial Bladder Cancer without Concomitant CIS Treated with Conservative Therapy Takashi Saika, Tomoyasu Tsushima, Yasutomo Nasu, Ryoji Arata,

More information

Should the primary be treated in patients with metastatic disease? Upper Tract Urothelial Cancer

Should the primary be treated in patients with metastatic disease? Upper Tract Urothelial Cancer Should the primary be treated in patients with metastatic disease? Upper Tract Urothelial Cancer Seth P. Lerner, MD, FACS Professor, Scott Department of Urology Beth and Dave Swalm Chair in Urologic Oncology

More information

Urological Oncology INTRODUCTION. M Hammad Ather, Masooma Zaidi

Urological Oncology INTRODUCTION. M Hammad Ather, Masooma Zaidi Urological Oncology Predicting Recurrence and Progression in Non-Muscle- Invasive Bladder Cancer Using European Organization of Research and Treatment of Cancer Risk Tables M Hammad Ather, Masooma Zaidi

More information

A Fourteen-Year Review of Radical Cystectomy for Transitional Cell Carcinoma Demonstrating the Usefulness of the Concept of Lymph Node Density

A Fourteen-Year Review of Radical Cystectomy for Transitional Cell Carcinoma Demonstrating the Usefulness of the Concept of Lymph Node Density Clinical Urology TCC of the Bladder and Lymph Node Density International Braz J Urol Vol. 32 (5): 536-549, September - October, 2006 A Fourteen-Year Review of Radical Cystectomy for Transitional Cell Carcinoma

More information

ROBOTIC VS OPEN RADICAL CYSTECTOMY

ROBOTIC VS OPEN RADICAL CYSTECTOMY ROBOTIC VS OPEN RADICAL CYSTECTOMY A REVIEW Colin Lundeen December 14, 2016 Objectives Review the history of radical cystectomy Critically analyze recent RCTs comparing open radical cystectomy (ORC) to

More information

Upper Tract Tcc. Mohan Arianayagam FRACS (Urology)

Upper Tract Tcc. Mohan Arianayagam FRACS (Urology) Upper Tract Tcc Mohan Arianayagam FRACS (Urology) Epidemiology Peak incidence 75 to 79 years 2x more common in men 7% of all renal tumours 5% of all urothelial tumours Synchronous bilateral is rare ~ 1.6%

More information

Primary Small Cell Carcinoma Of The Bladder: A Case Report And Review Of The Literature

Primary Small Cell Carcinoma Of The Bladder: A Case Report And Review Of The Literature ISPUB.COM The Internet Journal of Urology Volume 7 Number 1 Primary Small Cell Carcinoma Of The Bladder: A Case Report And Review Of The Literature T Hsieh, J Aragon-Ching, J Saia, T Sotelo Citation T

More information

Controversies in the management of Non-muscle invasive bladder cancer

Controversies in the management of Non-muscle invasive bladder cancer Controversies in the management of Non-muscle invasive bladder cancer Sia Daneshmand, MD Associate Professor of Urology (Clinical Scholar) Director of Urologic Oncology Director of Clinical Research Urologic

More information

Management of High-Risk Non-Muscle Invasive Bladder Cancer. Seth P. Lerner, MD, FACS

Management of High-Risk Non-Muscle Invasive Bladder Cancer. Seth P. Lerner, MD, FACS Management of High-Risk Non-Muscle Invasive Bladder Cancer Seth P. Lerner, MD, FACS Professor of Urology, Beth and Dave Swalm Chair in Urologic Oncology, Scott Department of Urology, Baylor College of

More information

Upper urinary tract urothelial carcinomas (UTUC)

Upper urinary tract urothelial carcinomas (UTUC) Prognostic Role of Lymphovascular Invasion in Patients with Urothelial Carcinoma of the Upper Urinary Tract Manel Mellouli 1 *, Slim Charfi 1, Walid Smaoui 2, Rim Kallel 1, Abdelmajid Khabir 1, Mehdi Bouacida

More information

Urothelial carcinomas of the upper urinary tract how does UK practice compare with European guidelines: is there a difference?

Urothelial carcinomas of the upper urinary tract how does UK practice compare with European guidelines: is there a difference? 699543URO0010.1177/2051415817699543Journal of Clinical UrologyMoon et al. research-article2018 EAU Guidelines Urothelial carcinomas of the upper urinary tract how does UK practice compare with European

More information

Urethral recurrence after cystectomy: current preventative measures, diagnosis and management

Urethral recurrence after cystectomy: current preventative measures, diagnosis and management Urethral recurrence after cystectomy: current preventative measures, diagnosis and management Yvonne Chan*, Patrick Fisher*, Derya Tilki* and Christopher P.Evans* *Department of Urology, Medical Center,

More information

EAU MUSCLE-INVASIVE AND METASTATIC BLADDER CANCER

EAU MUSCLE-INVASIVE AND METASTATIC BLADDER CANCER EAU MUSLE-INVASIVE AND METASTATI LADDER ANER (Limited text update March 2016) J.A. Witjes (hair), E. ompérat, N.. owan, M. De Santis, G. Gakis, N. James, T. Lebret, A.G. van der Heijden, M.J. Ribal Guidelines

More information

BJUI. Invasive T1 bladder cancer: indications and rationale for radical cystectomy

BJUI. Invasive T1 bladder cancer: indications and rationale for radical cystectomy 2008 The Authors; Journal compilation 2008 BJU International Mini-review Article INVASIVE T1 BLADDER CANCER: INDICATIONS AND RATIONALE FOR RADICAL CYSTECTOMY STEIN and PENSON BJUI BJU INTERNATIONAL Invasive

More information

Issues in the Management of High Risk Superficial Bladder Cancer

Issues in the Management of High Risk Superficial Bladder Cancer Issues in the Management of High Risk Superficial Bladder Cancer MICHAEL A.S. JEWETT DIVISION OF UROLOGY, DEPARTMENT OF SURGICAL ONCOLOGY, PRINCESS MARGARET HOSPITAL & THE UNIVERSITY OF TORONTO 1 Carcinoma

More information

American Journals of Cancer Case Reports. A Rare Case of Rectal Metastasis from Sarcomatoid Variant of Urothelial Carcinoma: A Case Report

American Journals of Cancer Case Reports. A Rare Case of Rectal Metastasis from Sarcomatoid Variant of Urothelial Carcinoma: A Case Report American Journals of Cancer Case Reports Lin JYJ et al. American Journals of Cancer Case Reports 2014, 3:1-5 http://ivyunion.org/index.php/ajccr Page 1 of 5 Vol 3 Article ID 20140539, 5 pages Case Report

More information

MEDICAL POLICY SUBJECT: URINARY TUMOR MARKERS FOR BLADDER CANCER. POLICY NUMBER: CATEGORY: Technology Assessment

MEDICAL POLICY SUBJECT: URINARY TUMOR MARKERS FOR BLADDER CANCER. POLICY NUMBER: CATEGORY: Technology Assessment MEDICAL POLICY SUBJECT: URINARY TUMOR MARKERS FOR PAGE: 1 OF: 5 If a product excludes coverage for a service, it is not covered, and medical policy criteria do not apply. If a commercial product, including

More information

Collection of Recorded Radiotherapy Seminars

Collection of Recorded Radiotherapy Seminars IAEA Human Health Campus Collection of Recorded Radiotherapy Seminars http://humanhealth.iaea.org Conservative Treatment of Invasive Bladder Cancer Luis Souhami, MD Professor Department of Radiation Oncology

More information

Impact of invasive bladder cancer and orthotopic urinary diversion on general health-related quality of life: An SF-36 survey

Impact of invasive bladder cancer and orthotopic urinary diversion on general health-related quality of life: An SF-36 survey 758 Impact of invasive bladder cancer and orthotopic urinary diversion on general health-related quality of life: An SF-36 survey MINGYING YANG 1,2*, HAIFENG WANG 2*, JIANSONG WANG 2 and MINGHUI RUAN 1

More information

URINARY DIVERSIONS. Susan Hilton, MD and Nicholas Papanicolaou, MD Co-Chiefs, CT Section Hospital of the University of Pennsylvania

URINARY DIVERSIONS. Susan Hilton, MD and Nicholas Papanicolaou, MD Co-Chiefs, CT Section Hospital of the University of Pennsylvania URINARY DIVERSIONS Susan Hilton, MD and Nicholas Papanicolaou, MD Co-Chiefs, CT Section Hospital of the University of Pennsylvania Neither of us has any financial relationships with commercial interests

More information

The Depth of Tumor Invasion is Superior to 8 th AJCC/UICC Staging System to Predict Patients Outcome in Radical Cystectomy.

The Depth of Tumor Invasion is Superior to 8 th AJCC/UICC Staging System to Predict Patients Outcome in Radical Cystectomy. 30 th Congress of the European Society of Pathology Tuesday, September 11, 2018 The Depth of Tumor Invasion is Superior to 8 th AJCC/UICC Staging System to Predict Patients Outcome in Radical Cystectomy.

More information

Care of bladder cancer patients diagnosed in Northern Ireland 2010 & 2011 (Summary)

Care of bladder cancer patients diagnosed in Northern Ireland 2010 & 2011 (Summary) Care of bladder cancer patients diagnosed in 2010 & 2011 (Summary) Bannon, F., Ranaghan, L., & Gavin, A. (2014). Care of bladder cancer patients diagnosed in 2010 & 2011 (Summary). N. Cancer Registry,

More information

Recovery of sexual function after radical cystectomy with orthotopic neobladder

Recovery of sexual function after radical cystectomy with orthotopic neobladder Recovery of sexual function after radical cystectomy with orthotopic neobladder C. Gingu, V. Olaru, A. Dick, C. Baston, M. Crăsneanu, C. Surcel, S. Voinea, Liliana Domnişor, I. Sinescu Center of Urological

More information

The pathology of bladder cancer

The pathology of bladder cancer 1 The pathology of bladder cancer Charles Jameson Introduction Carcinoma of the bladder is the seventh most common cancer worldwide [1]. It comprises 3.2% of all cancers, with an estimated 260 000 new

More information

Metachronous anterior urethral metastasis of prostatic ductal adenocarcinoma

Metachronous anterior urethral metastasis of prostatic ductal adenocarcinoma http://dx.doi.org/10.7180/kmj.2016.31.1.66 KMJ Case Report Metachronous anterior urethral metastasis of prostatic ductal adenocarcinoma Jeong Hyun Oh 1, Taek Sang Kim 1, Hyun Yul Rhew 1, Bong Kwon Chun

More information

Bladder Cancer in Primary Care. Dr Penny Kehagioglou Consultant Clinical Oncologist

Bladder Cancer in Primary Care. Dr Penny Kehagioglou Consultant Clinical Oncologist Bladder Cancer in Primary Care Dr Penny Kehagioglou Consultant Clinical Oncologist Objectives Patient presentation in primary care Investigating bladder cancer Management of bladder cancer Differential

More information

Impact of adjuvant chemotherapy on patients with pathological Stage T3b and/or lymph node metastatic bladder cancer after radical cystectomy

Impact of adjuvant chemotherapy on patients with pathological Stage T3b and/or lymph node metastatic bladder cancer after radical cystectomy Japanese Journal of Clinical Oncology, 2015, 45(10) 963 967 doi: 10.1093/jjco/hyv098 Advance Access Publication Date: 29 July 2015 Original Article Original Article Impact of adjuvant chemotherapy on patients

More information

Organ-sparing treatment of invasive transitional cell bladder carcinoma

Organ-sparing treatment of invasive transitional cell bladder carcinoma Journal of BUON 7: 241-245, 2002 2002 Zerbinis Medical Publications. Printed in Greece ORIGINAL ARTICLE Organ-sparing treatment of invasive transitional cell bladder carcinoma C. Damyanov, B. Tsingilev,

More information

Management of High Grade, T1 Bladder Cancer Douglas S. Scherr, M.D.

Management of High Grade, T1 Bladder Cancer Douglas S. Scherr, M.D. Management of High Grade, T1 Bladder Cancer Douglas S. Scherr, M.D. Assistant Professor of Urology Clinical Director, Urologic Oncology Weill Medical College-Cornell University Estimated new cancer cases.

More information

models; Kaplan meier curves were also extrapolated for each cohort to compare disease specific and overall survival patterns.

models; Kaplan meier curves were also extrapolated for each cohort to compare disease specific and overall survival patterns. ; 21 Urological Oncology MUSCULARIS PROPRIA AND UPSTAGING OF ct1 BLADDER CANCER BADALATO ET AL. BJUI Does the presence of muscularis propria on transurethral resection of bladder tumour specimens affect

More information

The Clinical Impact of the Classification of Carcinoma In Situ on Tumor Recurrence and their Clinical Course in Patients with Bladder Tumor

The Clinical Impact of the Classification of Carcinoma In Situ on Tumor Recurrence and their Clinical Course in Patients with Bladder Tumor Original Article Japanese Journal of Clinical Oncology Advance Access published December 17, 2010 Jpn J Clin Oncol 2010 doi:10.1093/jjco/hyq228 The Clinical Impact of the Classification of Carcinoma In

More information

Guidelines on Non-muscle invasive Bladder Cancer (TaT1 and CIS)

Guidelines on Non-muscle invasive Bladder Cancer (TaT1 and CIS) Guidelines on Non-muscle invasive Bladder Cancer (TaT1 and CIS) M. Babjuk, W. Oosterlinck, R. Sylvester, E. Kaasinen, A. Böhle, J. Palou, M. Rouprêt European Association of Urology 2011 TABLE OF CONTENTS

More information

비뇨병리연구회공청회 조남훈 연세대학교병리학교실

비뇨병리연구회공청회 조남훈 연세대학교병리학교실 비뇨병리연구회공청회 조남훈 연세대학교병리학교실 종양분류코드 - 방광암 표재성방광암 근층비침윤암 (Ta, Tis/ T1) 종양분류코드 진단서 ICD vs. ICO 사보험지급기준 중증질환분류 암등록사업 공보험 80-90% 지급기준 0 기암 -pta, ptis 특이한유형 면역 / 항암치료필요 재발과병기진행 다발성여부 진단확정주체 병리진단서 임상소견서 의무기록사 종양분류코드의변천사

More information

Urinary Bladder, Ureter, and Renal Pelvis

Urinary Bladder, Ureter, and Renal Pelvis Urinary Bladder, Ureter, and Renal Pelvis Protocol applies to all carcinomas of the urinary bladder, ureter, and renal pelvis. Protocol revision date: January 2005 Based on AJCC/UICC TNM, 6th edition Procedures

More information

Trimodality Therapy for Muscle Invasive Bladder Cancer

Trimodality Therapy for Muscle Invasive Bladder Cancer Trimodality Therapy for Muscle Invasive Bladder Cancer Brita Danielson, MD, FRCPC Radiation Oncologist, Cross Cancer Institute Assistant Professor, Department of Oncology University of Alberta Edmonton,

More information

Influence of stage discrepancy on outcome in. in patients treated with radical cystectomy.

Influence of stage discrepancy on outcome in. in patients treated with radical cystectomy. Tumori, 96: 699-703, 2010 Influence of stage discrepancy on outcome in patients treated with radical cystectomy Ja Hyeon Ku 1, Kyung Chul Moon 2, Cheol Kwak 1, and Hyeon Hoe Kim 1 1 Department of Urology,

More information